A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma
Preprint
Abstract
Many cancer drugs only benefit a subset of the patients that receive them, but are often associated with serious side effects. Predictive classification methods that can identify which patients will benefit from a specific treatment are therefore of great clinical utility. We here introduce a novel machine learning method to identify predictive gene expression signatures, based on the idea that patients who received different treatments but exhibit similar expression profiles can be used to model response to the alternative treatment. We use this method to predict proteasome inhibitor benefit in Multiple Myeloma (MM). In a dataset of 910 MM patients we identify a 14-gene expression signature that can successfully predict benefit to the proteasome inhibitor bortezomib, with a hazard ratio of 0.47 (p = 0.04) in class ‘benefit’, while in class ‘no benefit’ the hazard ratio is 0.91 (p = 0.68). Importantly, we observe a similar classification performance (HR class benefit = 0.46, p = 0.04) in an independent patient cohort which was moreover measured on a different platform, demonstrating the robustness of the signature. Moreover, we find that the genes in the discovered signature are essential, as no equivalent signature can be found when they are excluded from the analysis. Multiple genes in the signature are linked to working mechanisms of proteasome inhibitors or MM disease progression. In conclusion, our method allows for identification of gene expression signatures that can aid in treatment decisions for MM patients and provide insight into the biological mechanism behind treatment benefit.Keywords
All Related Versions
- Published version: Clinical Cancer Research, 26 (22), 5952.
This publication has 42 references indexed in Scilit:
- Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2018
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBlood, 2018
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive reviewExpert Opinion on Drug Metabolism & Toxicology, 2016
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismLeukemia, 2016
- Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With BortezomibClinical Lymphoma Myeloma and Leukemia, 2013
- Proteasome inhibitors in multiple myeloma: 10 years laterBlood, 2012
- Multiple MyelomaAnnual Review of Medicine, 2011
- Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.Journal of Clinical Oncology, 2010
- Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cellsLeukemia & Lymphoma, 2009